TY - JOUR
KW - Adult
KW - Delivery of Health Care
KW - Disease Progression
KW - Humans
KW - Incidence
KW - *Pulmonary Disease, Chronic Obstructive
KW - Severity of Illness Index
KW - United Kingdom/epidemiology
KW - Copd
KW - exacerbations of COPD
AU - H. Whittaker
AU - A. Rubino
AU - H. Mullerova
AU - T. Morris
AU - P. Varghese
AU - Y. Xu
AU - E. de Nigris
AU - J. Quint
AD - National Heart and Lung Institute, Imperial College London, London, UK.
Epidemiology, AstraZeneca, Cambridge, UK.
Medical and Scientific Affairs, AstraZeneca, Luton, UK.
Biopharmaceuticals Medical, Respiratory and Immunology, AstraZeneca, Gaithersburg, MD, USA.
Health Economics, AstraZeneca, Cambridge, UK.
AN - 35264849
BT - Int J Chron Obstruct Pulmon Dis
C2 - PMC8901192
DO - 10.2147/copd.s346591
DP - NLM
ET - 2022/03/11
LA - eng
N1 - 1178-2005
Whittaker, Hannah
Rubino, Annalisa
Müllerová, Hana
Morris, Tamsin
Orcid: 0000-0003-4475-5483
Varghese, Precil
Xu, Yang
De Nigris, Enrico
Quint, Jennifer K
Orcid: 0000-0003-0149-4869
Journal Article
Int J Chron Obstruct Pulmon Dis. 2022 Mar 3;17:427-437. doi: 10.2147/COPD.S346591. eCollection 2022.
PY - 2022
SN - 1176-9106 (Print)1176-9106
SP - 427
EP - 437
T2 - Int J Chron Obstruct Pulmon Dis
TI - Frequency and Severity of Exacerbations of COPD Associated with Future Risk of Exacerbations and Mortality: A UK Routine Health Care Data Study
VL - 17
ER -